DCAT Value Chain Insights’ Production to Prescription
DCAT
53 episodes
3 weeks ago
Without question, evolving US tariff and trade policy was the story of the year, and how such policy will be implemented looms large. At the same time, the normal course of business in the bio/pharmaceutical industry—new drug approvals and the progression of pipelines, including new modalities—was also top of mind. In this special episode of the Production to Prescription podcast, 2025: The Bio/Pharma Industry’s Year in Review, we provide key insights from industry experts and a snapshot of k...
All content for DCAT Value Chain Insights’ Production to Prescription is the property of DCAT and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Without question, evolving US tariff and trade policy was the story of the year, and how such policy will be implemented looms large. At the same time, the normal course of business in the bio/pharmaceutical industry—new drug approvals and the progression of pipelines, including new modalities—was also top of mind. In this special episode of the Production to Prescription podcast, 2025: The Bio/Pharma Industry’s Year in Review, we provide key insights from industry experts and a snapshot of k...
Biomanufacturing: How are Industry Capacity & Supply Chains Trending?
DCAT Value Chain Insights’ Production to Prescription
38 minutes
9 months ago
Biomanufacturing: How are Industry Capacity & Supply Chains Trending?
What is industry capacity utilization for biomanufacturing among the major systems/platforms (mammalian, microbial, and advanced therapies, and is there too much capacity or is the market tight? Is biomanufacturing outsourcing up or down? Are biopharma companies outsourcing more or less? Plus the impact on evolving trade policy on biomanufacturing supply chains. Featuring: Eric Langer, MBA, Managing Partner & President, BioPlan Associates and Renaud Jacquemart, PhD, MBA, Senior Advi...
DCAT Value Chain Insights’ Production to Prescription
Without question, evolving US tariff and trade policy was the story of the year, and how such policy will be implemented looms large. At the same time, the normal course of business in the bio/pharmaceutical industry—new drug approvals and the progression of pipelines, including new modalities—was also top of mind. In this special episode of the Production to Prescription podcast, 2025: The Bio/Pharma Industry’s Year in Review, we provide key insights from industry experts and a snapshot of k...
